Idoya Lahortiga

Idoya Lahortiga

UNVERIFIED PROFILE

Are you Idoya Lahortiga?   Register this Author

Register author
Idoya Lahortiga

Idoya Lahortiga

Publications by authors named "Idoya Lahortiga"

Are you Idoya Lahortiga?   Register this Author

34Publications

621Reads

30Profile Views

CD74-NRG1 fusions in lung adenocarcinoma.

Cancer Discov 2014 Apr 27;4(4):415-22. Epub 2014 Jan 27.

1Department of Translational Genomics; 2Department I of Internal Medicine; 3Laboratory of Translational Cancer Genomics; 4Network Genomic Medicine, University Hospital Cologne, Center of Integrated Oncology Cologne-Bonn; 5Center for Molecular Medicine Cologne (CMMC); 6Cologne Center for Genomics (CCG); 7Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD); 8Department of Pathology, University Hospital Medical Center, University of Cologne; 9Blackfield AG; 10Max Planck Institute for Neurological Research; 11Thoracic Surgery, Lungenklinik Merheim, Kliniken der Stadt Köln gGmbH; 12Institute of Human Genetics, Cologne; 13Computational Molecular Biology Department, Max Planck Institute for Molecular Genetics, Berlin; 14Department of Prostate Cancer Research, Institute of Pathology; 15Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn; 16Institute of Pathology; 17Department of Internal Medicine II, Jena University Hospital, Friedrich-Schiller-University, Jena; 18Institute for Pathology Bad Berka, Bad Berka, Germany;19Division of Molecular Oncology, Aichi Cancer Center Research Institute; 20Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan; Departments of 21Surgery and22Pathology, St. Vincent's Hospital; 23Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;24Department of Pathology, 25CHU Grenoble Institut National de la Santé et de la Recherche Medicale (INSERM) U823, Institute Albert Bonniot, Grenoble-Alpes University, Grenoble, France; 26Laboratory of Oncology IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo; 27Laboratory for Molecular Medicine and Biotechnology, University Campus Bio-Medico, Rome, Italy; 28Center for the Biology of Disease, VIB, Leuven; and 29Oncology Discovery, Janssen Research and Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0633DOI Listing
April 2014

Identification of novel FLT3 kinase inhibitors.

Eur J Med Chem 2013 May 21;63:713-21. Epub 2013 Mar 21.

Center for the Biology of Disease, VIB, Leuven 3000, Belgium.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S02235234130017
Publisher Site
http://dx.doi.org/10.1016/j.ejmech.2013.03.024DOI Listing
May 2013

Chromosomal aberrations and fusion genes in myeloid malignancies.

Expert Rev Hematol 2012 Aug;5(4):381-93

Center for Human Genetics, KU Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ehm.12.30DOI Listing
August 2012

Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia.

Nat Genet 2007 May 15;39(5):593-5. Epub 2007 Apr 15.

Human Genome Laboratory, Department of Molecular and Developmental Genetics, Vlaams Instituut voor Biotechnologie (VIB), Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng2025DOI Listing
May 2007

A novel t(2;3)(p11;q27) in a case of follicular lymphoma.

Cancer Genet Cytogenet 2007 Jan;172(1):70-3

IFOM, FIRC Institute for Molecular Oncology Foundation, Via Adamello 16, 20139 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergencyto.2006.07.017DOI Listing
January 2007

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.

Haematologica 2007 Jan;92(1):27-34

Department of Molecular and Developmental Genetics, Flanders Interuniversity Institute for Biotechnology (VIB), University of Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.10692DOI Listing
January 2007

FISH analysis of hematological neoplasias with 1p36 rearrangements allows the definition of a cluster of 2.5 Mb included in the minimal region deleted in 1p36 deletion syndrome.

Hum Genet 2005 May 3;116(6):476-85. Epub 2005 Mar 3.

Laboratory of Genetics, Division of Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pio XII, 55, 31080, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00439-005-1268-1DOI Listing
May 2005

NUP98 is fused to HOXA9 in a variant complex t(7;11;13;17) in a patient with AML-M2.

Cancer Genet Cytogenet 2005 Mar;157(2):151-6

Department of Genetics, School of Science, University of Navarra, C/ Irunlarrea s/n, 31008-Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergencyto.2004.08.001DOI Listing
March 2005

Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements.

Genes Chromosomes Cancer 2004 Jul;40(3):179-89

Department of Genetics, University of Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.20033DOI Listing
July 2004

TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia.

Mol Carcinog 2003 Dec;38(4):201-8

Department of Genetics, School of Sciences, University of Navarra, Pamplona, Navarra, Spain.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/mc.10159
Publisher Site
http://dx.doi.org/10.1002/mc.10159DOI Listing
December 2003

t(10;16)(q22;p13) and MORF-CREBBP fusion is a recurrent event in acute myeloid leukemia.

Genes Chromosomes Cancer 2003 Apr;36(4):402-5

Department of Genetics, School of Science, University of Navarra, C/Irunlarrea s/n, 31080 Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.10174DOI Listing
April 2003

Molecular cytogenetic characterization of breakpoints in 19 patients with hematologic malignancies and 12p unbalanced translocations.

Cancer Genet Cytogenet 2003 Apr;142(2):115-9

Department of Genetics, University of Navarra, C/ Irunlarrea s/n, 31008, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0165-4608(02)00728-8DOI Listing
April 2003